Cyclacel Pharmaceuticals (NASDAQ:CYCC) Coverage Initiated at StockNews.com

Equities research analysts at StockNews.com started coverage on shares of Cyclacel Pharmaceuticals (NASDAQ:CYCC) in a research report issued on Friday. The brokerage set a “sell” rating on the biotechnology company’s stock.

Cyclacel Pharmaceuticals Price Performance

Shares of NASDAQ CYCC opened at $0.33 on Friday. The stock has a market cap of $2.07 million, a PE ratio of -0.04 and a beta of 0.35. Cyclacel Pharmaceuticals has a 1 year low of $0.30 and a 1 year high of $4.00. The firm has a fifty day moving average price of $0.36 and a 200-day moving average price of $0.61.

Insider Buying and Selling at Cyclacel Pharmaceuticals

In related news, CEO David E. Lazar sold 194,628,820 shares of the stock in a transaction dated Wednesday, February 26th. The stock was sold at an average price of $0.03, for a total transaction of $5,838,864.60. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Insiders own 23.97% of the company’s stock.

Cyclacel Pharmaceuticals Company Profile

Cyclacel Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases in the United States, the United Kingdom, and internationally. The company's lead product includes fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors and hematological malignancies, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and Plogosertib, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced solid tumors and hematological malignancies.